08:00 , Feb 18, 2013 |  BC Week In Review  |  Company News

Brickell Biotech, Signum Dermatologix Inc. deal

Last December, Brickell terminated an April 2012 deal with Signum (formerly Argyle Therapeutics Inc. ) granting Brickell exclusive, worldwide rights to develop and commercialize SIG990 for dermatology indications. According to Signum, Brickell exited the deal...
08:00 , Feb 18, 2013 |  BioCentury  |  Emerging Company Profile

Signum: Rosacea double play

Therapies on the market or in development for rosacea treat either the symptomatic flushing or the inflammatory skin lesions. Signum Dermalogix Inc. 's lead small molecule isoprenylcysteine analog could treat both aspects of rosacea by...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Company News

Argyle Therapeutics, Brickell Biotech Inc deal

Argyle granted Brickell exclusive, worldwide rights to develop and commercialize SIG990 for dermatology indications. Argyle is eligible for milestones and royalties. The topical anti-inflammatory small molecule is in preclinical testing to treat rosacea. Details were...